The other peptide named RMS‐II was a lymphatic binding peptide similar to Lymphatic Peptide 1 (LyP‐1), a previously reported peptide for tumor targeting.[140] After the biotinylated RMS‐II peptide was injected into the RMS tumor‐bearing mice, a high fluorescence was detected in the tumor section, but little fluorescence was seen in the control tissue. The gene discussed is PTPN22; the disease is neoplasm.